{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:08Z","timestamp":1787020748273,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01 AG030142"],"award-info":[{"award-number":["NIH R01 AG030142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloid plaque deposition and axonal degeneration are early events in AD pathogenesis. A\u03b2 disrupts microtubules in presynaptic dystrophic neurites, resulting in the accumulation of impaired endolysosomal and autophagic organelles transporting \u03b2-site amyloid precursor protein cleaving enzyme (BACE1). Consequently, dystrophic neurites generate A\u03b242 and significantly contribute to plaque deposition. Farnesyltransferase inhibitors (FTIs) have recently been investigated for repositioning toward the treatment of neurodegenerative disorders and block the action of farnesyltransferase (FTase) to catalyze farnesylation, a post-translational modification that regulates proteins involved in lysosome function and microtubule stability. In postmortem AD brains, FTase and its downstream signaling are upregulated. However, the impact of FTIs on amyloid pathology and dystrophic neurites is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested the effects of the FTIs LNK-754 and lonafarnib in the 5XFAD mouse model of amyloid pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2-month-old 5XFAD mice treated chronically for 3\u2009months, LNK-754 reduced amyloid plaque burden, tau hyperphosphorylation, and attenuated the accumulation of BACE1\u00a0and LAMP1 in dystrophic neurites. In 5-month-old 5XFAD mice treated acutely for 3\u2009weeks, LNK-754 reduced dystrophic neurite size and LysoTracker-Green accumulation in the absence of effects on A\u03b2 deposits. Acute treatment with LNK-754 improved memory and learning deficits in hAPP\/PS1 amyloid mice. In contrast to LNK-754, lonafarnib treatment was less effective at reducing plaques, tau hyperphosphorylation and dystrophic neurites, which could have resulted from reduced potency against FTase compared to LNK-754. We investigated the effects of FTIs on axonal trafficking of endolysosomal organelles and found that lonafarnib and LNK-754 enhanced retrograde axonal transport in primary neurons, indicating FTIs could support the maturation of axonal late endosomes into lysosomes. Furthermore, FTI treatment increased levels of LAMP1 in mouse primary neurons and in the brains of 5XFAD mice, demonstrating that FTIs stimulated the biogenesis of endolysosomal organelles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We show new data to suggest that LNK-754 promoted the axonal trafficking and function of endolysosomal compartments, which we hypothesize decreased axonal dystrophy, reduced BACE1 accumulation and inhibited amyloid deposition in 5XFAD mice. Our results agree with previous work identifying FTase as a therapeutic target for treating proteinopathies and could have important therapeutic implications in treating AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-022-00561-9","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T01:02:58Z","timestamp":1660957378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice"],"prefix":"10.1186","volume":"17","author":[{"given":"Leah K.","family":"Cuddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia O.","family":"Alia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda A.","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhanth","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom N.","family":"Grammatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Justman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Peter T.","family":"Lansbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Mazzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1358-504X","authenticated-orcid":false,"given":"Robert","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"issue":"10","key":"561_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12(10):383\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"5580","key":"561_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science."},{"issue":"4","key":"561_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6(4):487\u201398.","journal-title":"Neuron."},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"PP Liu","year":"2019","unstructured":"Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduct Target Ther. 2019;4:29.","journal-title":"Signal Transduct Target Ther"},{"issue":"7618","key":"561_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature."},{"issue":"563","key":"561_CR6","doi-asserted-by":"publisher","first-page":"eaaz2541","DOI":"10.1126\/scitranslmed.aaz2541","volume":"12","author":"LK Cuddy","year":"2020","unstructured":"Cuddy LK, Prokopenko D, Cunningham EP, Brimberry R, Song P, Kirchner R, et al. A\u03b2-accelerated neurodegeneration caused by Alzheimer's-associated. Sci Transl Med. 2020;12(563):eaaz2541.","journal-title":"Sci Transl Med"},{"issue":"1","key":"561_CR7","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","volume":"6","author":"J Cummings","year":"2020","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6(1):e12050.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"561_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.neuron.2019.09.001","volume":"104","author":"LK Cuddy","year":"2019","unstructured":"Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, et al. Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by \u03b1-Synuclein. Neuron. 2019;104(5):869\u201384.e11.","journal-title":"Neuron."},{"issue":"485","key":"561_CR9","doi-asserted-by":"publisher","first-page":"eaat3005","DOI":"10.1126\/scitranslmed.aat3005","volume":"11","author":"I Hernandez","year":"2019","unstructured":"Hernandez I, Luna G, Rauch JN, Reis SA, Giroux M, Karch CM, et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Sci Transl Med. 2019;11(485):eaat3005.","journal-title":"Sci Transl Med"},{"issue":"29","key":"561_CR10","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, et al. Activation of \u03b2-Glucocerebrosidase reduces pathological \u03b1-Synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J Neurosci. 2016;36(29):7693\u2013706.","journal-title":"J Neurosci"},{"issue":"8","key":"561_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.3232","volume":"19","author":"RA Nixon","year":"2013","unstructured":"Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983\u201397.","journal-title":"Nat Med"},{"issue":"12","key":"561_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","volume":"18","author":"SR Bonam","year":"2019","unstructured":"Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019;18(12):923\u201348.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"561_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-019-0323-7","volume":"14","author":"ZP Van Acker","year":"2019","unstructured":"Van Acker ZP, Bretou M, Annaert W. Endo-lysosomal dysregulations and late-onset Alzheimer's disease: impact of genetic risk factors. Mol Neurodegener. 2019;14(1):20.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"561_CR14","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41380-019-0396-2","volume":"24","author":"MG Sharoar","year":"2019","unstructured":"Sharoar MG, Hu X, Ma XM, Zhu X, Yan R. Sequential formation of different layers of dystrophic neurites in Alzheimer's brains. Mol Psychiatry. 2019;24(9):1369\u201382.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"561_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/exnr.1998.7010","volume":"156","author":"TC Dickson","year":"1999","unstructured":"Dickson TC, King CE, McCormack GH, Vickers JC. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp Neurol. 1999;156(1):100\u201310.","journal-title":"Exp Neurol"},{"issue":"2","key":"561_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","volume":"132","author":"KR Sadleir","year":"2016","unstructured":"Sadleir KR, Kandalepas PC, Buggia-Prevot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer's disease. Acta Neuropathol. 2016;132(2):235\u201356.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"561_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00401-013-1152-3","volume":"126","author":"PC Kandalepas","year":"2013","unstructured":"Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer's \u03b2-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126(3):329\u201352.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"561_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00401-017-1804-9","volume":"135","author":"F Peters","year":"2018","unstructured":"Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S, et al. BACE1 inhibition more effectively suppresses initiation than progression of \u03b2-amyloid pathology. Acta Neuropathol. 2018;135(5):695\u2013710.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"561_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-020-00662-x","volume":"12","author":"J Bauzon","year":"2020","unstructured":"Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer's disease drug development pipeline. Alzheimers Res Ther. 2020;12(1):98.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"561_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1039\/C7MD00030H","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. Medchemcomm. 2017;8(5):841\u201354.","journal-title":"Medchemcomm."},{"issue":"7","key":"561_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1517\/13543784.2012.688950","volume":"21","author":"NS Wong","year":"2012","unstructured":"Wong NS, Morse MA. Lonafarnib for cancer and progeria. Expert Opin Investig Drugs. 2012;21(7):1043\u201355.","journal-title":"Expert Opin Investig Drugs"},{"issue":"14","key":"561_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.4155\/fmc.11.121","volume":"3","author":"AT Baines","year":"2011","unstructured":"Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3(14):1787\u2013808.","journal-title":"Future Med Chem"},{"issue":"3","key":"561_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","volume":"63","author":"SJ McTaggart","year":"2006","unstructured":"McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci. 2006;63(3):255\u201367.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"561_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1074\/mcp.M900597-MCP200","volume":"9","author":"FO Onono","year":"2010","unstructured":"Onono FO, Morgan MA, Spielmann HP, Andres DA, Subramanian T, Ganser A, et al. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics. 2010;9(4):742\u201351.","journal-title":"Mol Cell Proteomics"},{"issue":"21","key":"561_CR25","doi-asserted-by":"publisher","first-page":"12042","DOI":"10.3390\/ijms222112042","volume":"22","author":"GL Schey","year":"2021","unstructured":"Schey GL, Buttery PH, Hildebrandt ER, Novak SX, Schmidt WK, Hougland JL, et al. MALDI-MS analysis of peptide libraries expands the scope of substrates for farnesyltransferase. Int J Mol Sci. 2021;22(21):12042.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"561_CR26","doi-asserted-by":"publisher","first-page":"e0122830","DOI":"10.1371\/journal.pone.0122830","volume":"10","author":"L Sun","year":"2015","unstructured":"Sun L, Xie S, Peng G, Wang J, Li Y, Qin J, et al. Lonafarnib is a potential inhibitor for neovascularization. PLoS One. 2015;10(4):e0122830.","journal-title":"PLoS One"},{"issue":"1","key":"561_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/auto.5.1.7329","volume":"5","author":"J Pan","year":"2009","unstructured":"Pan J, Song E, Cheng C, Lee MH, Yeung SC. Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms? Autophagy. 2009;5(1):129\u201331.","journal-title":"Autophagy."},{"issue":"12","key":"561_CR28","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1073\/pnas.0806474106","volume":"106","author":"Z Liu","year":"2009","unstructured":"Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, et al. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A. 2009;106(12):4635\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"561_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1042\/BST0380287","volume":"38","author":"IS Mehta","year":"2010","unstructured":"Mehta IS, Bridger JM, Kill IR. Progeria, the nucleolus and farnesyltransferase inhibitors. Biochem Soc Trans. 2010;38(Pt 1):287\u201391.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"561_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40478-021-01231-5","volume":"9","author":"A Jeong","year":"2021","unstructured":"Jeong A, Cheng S, Zhong R, Bennett DA, Berg\u00f6 MO, Li L. Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice. Acta Neuropathol Commun. 2021;9(1):129.","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"561_CR31","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1158\/0008-5472.CAN-04-3757","volume":"65","author":"AI Marcus","year":"2005","unstructured":"Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 2005;65(9):3883\u201393.","journal-title":"Cancer Res"},{"issue":"5","key":"561_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s002800000170","volume":"46","author":"B Shi","year":"2000","unstructured":"Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 2000;46(5):387\u201393.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"561_CR33","doi-asserted-by":"publisher","first-page":"9648","DOI":"10.1074\/jbc.M808708200","volume":"284","author":"J Zhou","year":"2009","unstructured":"Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, et al. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem. 2009;284(15):9648\u201355.","journal-title":"J Biol Chem"},{"issue":"1","key":"561_CR34","doi-asserted-by":"publisher","first-page":"14776","DOI":"10.1038\/s41598-020-71767-4","volume":"10","author":"JJ Fernandez-Valenzuela","year":"2020","unstructured":"Fernandez-Valenzuela JJ, Sanchez-Varo R, Mu\u00f1oz-Castro C, De Castro V, Sanchez-Mejias E, Navarro V, et al. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer's disease model. Sci Rep. 2020;10(1):14776.","journal-title":"Sci Rep"},{"key":"561_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fncel.2018.00226","volume":"12","author":"A Varidaki","year":"2018","unstructured":"Varidaki A, Hong Y, Coffey ET. Repositioning microtubule stabilizing drugs for brain disorders. Front Cell Neurosci. 2018;12:226.","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"561_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-143120","volume":"45","author":"BC Richard","year":"2015","unstructured":"Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2015;45(4):1223\u201336.","journal-title":"J Alzheimers Dis"},{"issue":"40","key":"561_CR37","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nbd.2016.01.001","volume":"88","author":"P Giannoni","year":"2016","unstructured":"Giannoni P, Arango-Lievano M, Neves ID, Rousset MC, Baranger K, Rivera S, et al. Cerebrovascular pathology during the progression of experimental Alzheimer's disease. Neurobiol Dis. 2016;88:107\u201317.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"561_CR39","doi-asserted-by":"publisher","first-page":"196.e29","DOI":"10.1016\/j.neurobiolaging.2010.05.027","volume":"33","author":"S Jawhar","year":"2012","unstructured":"Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A\u03b2 aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging. 2012;33(1):196.e29\u201340.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"561_CR40","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1074\/jbc.274.10.6483","volume":"274","author":"D Moechars","year":"1999","unstructured":"Moechars D, Dewachter I, Lorent K, Revers\u00e9 D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274(10):6483\u201392.","journal-title":"J Biol Chem"},{"issue":"21","key":"561_CR41","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-04-0901","volume":"10","author":"SL Moulder","year":"2004","unstructured":"Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, et al. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004;10(21):7127\u201335.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"561_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2001.19.4.1167","volume":"19","author":"FA Eskens","year":"2001","unstructured":"Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001;19(4):1167\u201375.","journal-title":"J Clin Oncol"},{"issue":"28","key":"561_CR43","doi-asserted-by":"publisher","first-page":"E3699","DOI":"10.1073\/pnas.1510329112","volume":"112","author":"S Gowrishankar","year":"2015","unstructured":"Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc Natl Acad Sci U S A. 2015;112(28):E3699\u2013708.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"561_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-011-0627-0","volume":"105","author":"A Desjardins","year":"2011","unstructured":"Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE, et al. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neuro-Oncol. 2011;105(3):601\u20136.","journal-title":"J Neuro-Oncol"},{"key":"561_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-10-1","volume":"10","author":"KR Sadleir","year":"2015","unstructured":"Sadleir KR, Eimer WA, Cole SL, Vassar R. A\u03b2 reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener. 2015;10:1.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"561_CR46","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cne.24551","volume":"527","author":"JL Bundy","year":"2019","unstructured":"Bundy JL, Vied C, Badger C, Nowakowski RS. Sex-biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: a multi-omic analysis. J Comp Neurol. 2019;527(2):462\u201375.","journal-title":"J Comp Neurol"},{"issue":"1","key":"561_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1096\/fj.12-217497","volume":"27","author":"V Shukla","year":"2013","unstructured":"Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, et al. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J. 2013;27(1):174\u201386.","journal-title":"FASEB J"},{"key":"561_CR48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.bbr.2014.08.034","volume":"274","author":"T Kanno","year":"2014","unstructured":"Kanno T, Tsuchiya A, Nishizaki T. Hyperphosphorylation of tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav Brain Res. 2014;274:302\u20136.","journal-title":"Behav Brain Res"},{"issue":"2","key":"561_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.neuroscience.2010.04.009","volume":"168","author":"J Bertrand","year":"2010","unstructured":"Bertrand J, Plouffe V, S\u00e9n\u00e9chal P, Leclerc N. The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience. 2010;168(2):323\u201334.","journal-title":"Neuroscience."},{"issue":"6","key":"561_CR50","first-page":"2318","volume":"6","author":"AA Adjei","year":"2000","unstructured":"Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6(6):2318\u201325.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"561_CR51","first-page":"4947","volume":"58","author":"M Liu","year":"1998","unstructured":"Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998;58(21):4947\u201356.","journal-title":"Cancer Res"},{"key":"561_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.conb.2018.02.020","volume":"51","author":"SM Ferguson","year":"2018","unstructured":"Ferguson SM. Axonal transport and maturation of lysosomes. Curr Opin Neurobiol. 2018;51:45\u201351.","journal-title":"Curr Opin Neurobiol"},{"issue":"4","key":"561_CR53","doi-asserted-by":"publisher","first-page":"109034","DOI":"10.1016\/j.celrep.2021.109034","volume":"35","author":"PPY Lie","year":"2021","unstructured":"Lie PPY, Yang DS, Stavrides P, Goulbourne CN, Zheng P, Mohan PS, et al. Post-Golgi carriers, not lysosomes, confer lysosomal properties to pre-degradative organelles in normal and dystrophic axons. Cell Rep. 2021;35(4):109034.","journal-title":"Cell Rep"},{"issue":"5","key":"561_CR54","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4161\/auto.6259","volume":"4","author":"RA Nixon","year":"2008","unstructured":"Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008;4(5):590\u20139.","journal-title":"Autophagy."},{"issue":"15","key":"561_CR55","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/cncr.28031","volume":"119","author":"S Yust-Katz","year":"2013","unstructured":"Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, et al. Phase 1\/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 2013;119(15):2747\u201353.","journal-title":"Cancer."},{"issue":"1","key":"561_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"561_CR57","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2006.09.4243","volume":"25","author":"MW Kieran","year":"2007","unstructured":"Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a pediatric brain tumor consortium study. J Clin Oncol. 2007;25(21):3137\u201343.","journal-title":"J Clin Oncol"},{"issue":"10","key":"561_CR58","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2174\/1568026033452050","volume":"3","author":"M Venet","year":"2003","unstructured":"Venet M, End D, Angibaud P. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery. Curr Top Med Chem. 2003;3(10):1095\u2013102.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"561_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-021-00464-1","volume":"16","author":"MG Sharoar","year":"2021","unstructured":"Sharoar MG, Palko S, Ge Y, Saido TC, Yan R. Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains. Mol Neurodegener. 2021;16(1):45.","journal-title":"Mol Neurodegener"},{"issue":"19","key":"561_CR60","doi-asserted-by":"publisher","first-page":"16161","DOI":"10.1074\/jbc.M006213200","volume":"276","author":"NC Crespo","year":"2001","unstructured":"Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001;276(19):16161\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"561_CR61","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/cncr.21188","volume":"104","author":"ES Kim","year":"2005","unstructured":"Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory\/resistant nonsmall cell lung carcinoma. Cancer. 2005;104(3):561\u20139.","journal-title":"Cancer."},{"issue":"50","key":"561_CR62","doi-asserted-by":"publisher","first-page":"35952","DOI":"10.1074\/jbc.M113.503904","volume":"288","author":"S Cheng","year":"2013","unstructured":"Cheng S, Cao D, Hottman DA, Yuan L, Bergo MO, Li L. Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease. J Biol Chem. 2013;288(50):35952\u201360.","journal-title":"J Biol Chem"},{"issue":"3","key":"561_CR63","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s12035-020-02169-w","volume":"58","author":"W Qu","year":"2021","unstructured":"Qu W, Suazo KF, Liu W, Cheng S, Jeong A, Hottman D, et al. Neuronal protein Farnesylation regulates hippocampal synaptic plasticity and cognitive function. Mol Neurobiol. 2021;58(3):1128\u201344.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"561_CR64","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1074\/jbc.M113.536912","volume":"289","author":"RG Mealer","year":"2014","unstructured":"Mealer RG, Murray AJ, Shahani N, Subramaniam S, Snyder SH. Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. J Biol Chem. 2014;289(6):3547\u201354.","journal-title":"J Biol Chem"},{"issue":"6","key":"561_CR65","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41557-019-0237-6","volume":"11","author":"EM Storck","year":"2019","unstructured":"Storck EM, Morales-Sanfrutos J, Serwa RA, Panyain N, Lanyon-Hogg T, Tolmachova T, et al. Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics. Nat Chem. 2019;11(6):552\u201361.","journal-title":"Nat Chem"},{"issue":"3","key":"561_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/10409238.2018.1458070","volume":"53","author":"A Jeong","year":"2018","unstructured":"Jeong A, Suazo KF, Wood WG, Distefano MD, Li L. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. Crit Rev Biochem Mol Biol. 2018;53(3):279\u2013310.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"4","key":"561_CR67","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jshs.2016.10.004","volume":"5","author":"R Vassar","year":"2016","unstructured":"Vassar R. BACE1 inhibition as a therapeutic strategy for Alzheimer's disease. J Sport Health Sci. 2016;5(4):388\u201390.","journal-title":"J Sport Health Sci"},{"issue":"11","key":"561_CR68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","volume":"17","author":"E McDade","year":"2021","unstructured":"McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol. 2021;17(11):703\u201314.","journal-title":"Nat Rev Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00561-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T18:44:56Z","timestamp":1700937896000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00561-9","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"25 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal work was done in accordance with Northwestern University Institutional Animal Care and Use Committee (IACUC) approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JRM is a scientific co-founder of Lysosomal Therapeutics, INC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}